Jikei University   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Tokyo Japan (1877)

Organization Overview

First Clinical Trial
2002
NCT00133328
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan | Jikei University School of Medicine | The Jikei University School of Medicine

Active Ingredients

Drugs in Phase 4 Trials (1)

valsartan (diovan) (1 trial)

Drugs in Phase 3 Trials (5)

calcipotriene (dovonex) (1 trial)

calcipotriol (1 trial)

carboplatin (paraplatin) (1 trial)

infliximab (remicade) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Other Trials (1)

insulin human (humulin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis, Psoriatic (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Coronary Artery Disease (Phase 4)

Dermatitis, Exfoliative (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Hypertension (Phase 4)

Myocardial Ischemia (Phase 4)

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7